Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats

Neurobiology of Aging

Volumn 36, Issue 1, 2015, Pages 505-518

  Lee, Jang Won ^a   Tapias, Victor ^b   Di Maio, Roberto ^b,c   Greenamyre, J Timothy ^b   Cannon, Jason R ^a  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c RiMED Foundation   (Italy)

Author keywords

Inflammation; Leucine rich repeat kinase 2; Neurodegeneration; Oxidative stress; Parkinson's disease

Indexed keywords

3 NITROTYROSINE; DOPAMINE; GLYCINE; INDUCIBLE NITRIC OXIDE SYNTHASE; LEUCINE RICH REPEAT KINASE 2; SERINE; SEROTONIN; LRRK2 PROTEIN, HUMAN; LRRK2 PROTEIN, RAT; PROTEIN SERINE THREONINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BACTERIAL ARTIFICIAL CHROMOSOME; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; GENE MUTATION; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROCHEMISTRY; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; RAT; REARING; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; TRANSGENIC RAT; WILD TYPE; ANIMAL; DISEASE MODEL; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; METABOLISM; MUTATION; PARKINSONISM; SPRAGUE DAWLEY RAT;

ANIMALS; CHROMOSOMES, ARTIFICIAL, BACTERIAL; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; GENE-ENVIRONMENT INTERACTION; HUMANS; MUTATION; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; PROTEIN-SERINE-THREONINE KINASES; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC;

EID: 84920406808     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.07.011     Document Type: Article

References (52)

1. Biskup S., Moore D.J., Celsi F., Higashi S., West A.B., Andrabi S.A., Kurkinen K., Yu S.W., Savitt J.M., Waldvogel H.J., Faull R.L., Emson P.C., Torp R., Ottersen P., Dawson V.L. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 2006, 60:557-569.
2. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
3. Cannon J.R., Greenamyre J.T. Neurotoxic invivo models of Parkinson's disease recent advances. Prog. Brain Res. 2010, 184:17-33.
4. Cannon J.R., Tapias V., Na H.M., Honick A.S., Drolet R.E., Greenamyre J.T. Ahighly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis. 2009, 34:279-290.
5. Cannon J.R., Sew T., Montero L., Burton E.A., Greenamyre J.T. Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra. Exp. Neurol. 2011, 228:41-52.
6. Cannon J.R., Geghman K.D., Tapias V., Sew T., Dail M.K., Li C., Greenamyre J.T. Expression of human E46K-mutated alpha-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment. Exp. Neurol. 2013, 240:44-56.
7. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
8. Davies P., Hinkle K.M., Sukar N.N., Sepulveda B., Mesias R., Serrano G., Alessi R., Beach T.G., Benson D.L., White C.L., Cowell R.M., Das S.S., West A.B., Melrose H.L. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. Biochem. J. 2013, 453:101-113.
9. Doherty G.H. Nitric oxide in neurodegeneration: potential benefits of non-steroidal anti-inflammatories. Neurosci. Bull. 2011, 27:366-382.
10. Dusonchet J., Kochubey O., Stafa K., Young S.M., Zufferey R., Moore D.J., Schneider B.L., Aebischer P. Arat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J.Neurosci. 2011, 31:907-912.
11. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 1992, 32:804-812.
12. Fleming S.M., Zhu C., Fernagut P.O., Mehta A., DiCarlo C.D., Seaman R.L., Chesselet M.F. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp. Neurol. 2004, 187:418-429.
13. Forno L.S. Neuropathology of Parkinson's disease. J.Neuropathol. Exp. Neurol. 1996, 55:259-272.
14. Gandhi P.N., Chen S.G., Wilson-Delfosse A.L. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. J.Neurosci. Res. 2009, 87:1283-1295.
15. Giasson B.I., Covy J.P., Bonini N.M., Hurtig H.I., Farrer M.J., Trojanowski J.Q., Van Deerlin V.M. Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 2006, 59:315-322.
16. Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A., Lees A.J., Shaw K., Bhatia K.P., Bonifati V., Quinn N.P., Lynch J., Healy D.G., Holton J.L., Revesz T., Wood N.W. Acommon LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005, 365:415-416.
17. Gloeckner C.J., Schumacher A., Boldt K., Ueffing M. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, invitro. J.Neurochem. 2009, 109:959-968.
18. Gnegy M.E. Catecholamines. Basic Neurochemistry. Principles of Molecular, Cellular, and Medical Neurobiology 2012, 283-299. Oxford University Press, New York, United States. eighth ed. S.T. Brady, G.J. Siegel, R.W. Albers, D.L. Price (Eds.).
19. Guo L., Wang W., Chen S.G. Leucine-rich repeat kinase 2: relevance to Parkinson's disease. Int. J. Biochem. Cell Biol 2006, 38:1469-1475.
20. Halliwell B., Gutteridge J.M.C. Reactive species can be poisonous. Free Radicals in Biology and Medicine 2007, 440-487. Oxford University Press, New York, United States. fourth ed. B. Halliwell, J.M.C. Gutteridge (Eds.).
21. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., Brice A., Aasly J., Zabetian C.P., Goldwurm S., Ferreira J.J., Tolosa E., Kay D.M., Klein C., Williams D.R., Marras C., Lang A.E., Wszolek Z.K., Berciano J., Schapira H., Lynch T., Bhatia K.P., Gasser T., Lees A.J., Wood N.W. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008, 7:583-590.
22. Herzig M.C., Bidinosti M., Schweizer T., Hafner T., Stemmelen C., Weiss A., Danner S., Vidotto N., Stauffer D., Barske C., Mayer F., Schmid P., Rovelli G., van der Putten P.H., Shimshek D.R. High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One 2012, 7:e36581.
23. Horowitz M.P., Milanese C., Di Maio R., Hu X., Montero L.M., Sanders L.H., Tapias V., Sepe S., van Cappellen A., Burton E.A., Greenamyre J.T., Mastroberardino P.G. Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults. Antioxid. Redox Signal 2011, 15:855-871.
24. Kermer P., Krajewska M., Zapata J.M., Takayama S., Mai J., Krajewski S., Reed J.C. Bag1 is a regulator and marker of neuronal differentiation. Cell Death Differ. 2002, 9:405-413.
25. Kiernan J.A. Histological staining in one or two colours, Chapter 6. Histological and Histochemical Methods 2008, Scion Publishing Ltd, Oxfordshire, United Kingdom. fourth ed.
26. LaFerla F.M., Troncoso J.C., Strickland D.K., Kawas C.H., Jay G. Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. J.Clin. Invest. 1997, 100:310-320.
27. Lee B.D., Shin J.H., VanKampen J., Petrucelli L., West A.B., Ko H.S., Lee Y.I., Maguire-Zeiss K.A., Bowers W.J., Federoff H.J., Dawson V.L., Dawson T.M. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat. Med. 2010, 16:998-1000.
28. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 1999, 5:1403-1409.
29. Li Y., Liu W., Oo T.F., Wang L., Tang Y., Jackson-Lewis V., Zhou C., Geghman K., Bogdanov M., Przedborski S., Beal M.F., Burke R.E., Li C. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 2009, 12:826-828.
30. Li X., Patel J.C., Wang J., Avshalumov M.V., Nicholson C., Buxbaum J.D., Elder A., Rice M.E., Yue Z. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J.Neurosci. 2010, 30:1788-1797.
31. Lin X., Parisiadou L., Gu X.L., Wang L., Shim H., Sun L., Xie C., Long C.X., Yang W.J., Ding J., Chen Z.Z., Gallant P.E., Tao-Cheng J.H., Rudow G., Troncoso J.C., Liu Z., Li Z., Cai H. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009, 64:807-827.
32. Liu Z., Lenardo M.J. The role of LRRK2 in inflammatory bowel disease. Cell Res. 2012, 22:1092-1094.
33. Liu Z., Lee J., Krummey S., Lu W., Cai H., Lenardo M.J. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat. Immunol. 2011, 12:1063-1070.
34. MacLeod D., Dowman J., Hammond R., Leete T., Inoue K., Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006, 52:587-593.
35. Melrose H.L., Dachsel J.C., Behrouz B., Lincoln S.J., Yue M., Hinkle K.M., Kent B., Korvatska E., Taylor J.P., Witten L., Liang Y.Q., Beevers J.E., Boules M., Dugger B.N., Serna V.A., Gaukhman A., Yu X., Castanedes-Casey M., Braithwaite A.T., Ogholikhan S., Yu N., Bass D., Tyndall G., Schellenberg G.D., Dickson D.W., Janus C., Farrer M.J. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol. Dis. 2010, 40:503-517.
36. Moehle M.S., Webber P.J., Tse T., Sukar N., Standaert D.G., DeSilva T.M., Cowell R.M., West A.B. LRRK2 inhibition attenuates microglial inflammatory responses. J.Neurosci. 2012, 32:1602-1611.
37. Piccoli G., Condliffe S.B., Bauer M., Giesert F., Boldt K., De Astis S., Meixner A., Sarioglu H., Vogt-Weisenhorn D.M., Wurst W., Gloeckner C.J., Matteoli M., Sala C., Ueffing M. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J.Neurosci. 2011, 31:2225-2237.
38. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150:76-85.
39. Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B., Dawson V.L., Dawson T.M., Ross C.A. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A 2005, 102:18676-18681.
40. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 2006, 9:1231-1233.
41. Tapias V., Greenamyre J.T. Arapid and sensitive automated image-based approach for invitro and invivo characterization of cell morphology and quantification of cell number and neurite architecture. Curr. Protoc. Cytom. 2014, 68:12 33 1-12 33 22.
42. Tapias V., Greenamyre J.T., Watkins S.C. Automated imaging system for fast quantitation of neurons, cell morphology and neurite morphometry invivo and invitro. Neurobiol. Dis. 2013, 54:158-168.
43. Tapias V., Cannon J.R., Greenamyre J.T. Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease. Neurobiol. Aging 2014, 35:1162-1176.
44. Thakur P., Nehru B. Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease. Neuroscience 2013, 231:420-431.
45. Tillerson J.L., Cohen A.D., Philhower J., Miller G.W., Zigmond M.J., Schallert T. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J.Neurosci. 2001, 21:4427-4435.
46. Tong Y., Pisani A., Martella G., Karouani M., Yamaguchi H., Pothos E.N., Shen J. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. U.S.A 2009, 106:14622-14627.
47. Tufekci K.U., Meuwissen R., Genc S., Genc K. Inflammation in Parkinson's disease. Adv. Protein Chem. Struct. Biol. 2012, 88:69-132.
48. Wang Y., Lee J.W., Oh G., Grady S.R., McIntosh J.M., Brunzell D.H., Cannon J.R., Drenan R.M. Enhanced synthesis and release of dopamine in transgenic mice with gain-of-function alpha6* nAChRs. J.Neurochem. 2014, 129:315-327.
49. Woodlee M.T., Kane J.R., Chang J., Cormack L.K., Schallert T. Enhanced function in the good forelimb of hemi-parkinson rats: compensatory adaptation for contralateral postural instability?. Exp. Neurol. 2008, 211:511-517.
50. West A.B., Cowell R.M., Daher J.P., Moehle M.S., Hinkle K.M., Melrose H.L., Standaert D.G., Volpicelli-Daley L.A. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. J.Comp. Neurol. 2014, 522:2465-2480.
51. Yang D., Li T., Liu Z., Arbez N., Yan J., Moran T.H., Ross C.A., Smith W.W. LRRK2 kinase activity mediates toxic interactions between genetic mutation and oxidative stress in a Drosophila model: suppression by curcumin. Neurobiol. Dis. 2012, 47:385-392.
52. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Müller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.